Last reviewed · How we verify
NCT05994339
Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer
Phase 2, PHASE3 trial testing Almonertinib in Lung Cancer Stage III in 40 participants. Status unknown.
8 August 2025
Quick facts
| Lead sponsor | Laibin People's Hospital |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 September 2023 |
| Primary completion | 8 August 2025 |
| Estimated completion | 8 December 2025 |
Drugs / interventions tested
- Almonertinib — full drug profile →
Conditions studied
- Lung Cancer Stage III — all drugs for Lung Cancer Stage III →
Sponsor
Laibin People's Hospital
Who can join
Adults 18 to 80, any sex, with Lung Cancer Stage III. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Study Object: Stage III lung cancer with epidermal growth factor receptor (EGFR) sensitive mutation. Study Method: The study subjects will be randomly assigned to the intervention group and the control group. The intervention group will receive radiotherapy combined with erlotinib treatment, while the control group will receive concurrent radiotherapy combined with chemotherapy. The differences in short-term efficacy, long-term efficacy, and incidence of adverse reactions between the two groups will be observed. Observation Indicators: Short-term efficacy indicators: Complete remission (CR) rate, partial remission (PR) rate, and objective response rate (ORR). Long-term efficacy indicators: Overall survival (OS) and progression-free survival (PFS). Adverse reaction indicators: Incidence of lung toxicity, hematological toxicity, and gastrointestinal reactions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05994339
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Almonertinib
Trials testing the same drug.
- NCT06951464 — A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC · Phase 2 · recruiting
- NCT05768490 — Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastas · Phase 3 · recruiting
- NCT05662813 — Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Thera · Phase 2 · unknown
- NCT05503888 — Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Ca · Phase 1, PHASE2 · not yet recruiting
- NCT04841811 — MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model. · Phase 3 · recruiting
Other recruiting trials for Lung Cancer Stage III
Currently open trials in the same condition.
- NCT06968221 — Bovine Reinforcement in Stomach, Colorectal and Lung Operation · Phase 3 · recruiting
- NCT06563999 — Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. · Phase 2 · recruiting
- NCT06111807 — Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC · recruiting
- NCT03872661 — Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC · Phase 2 · recruiting
Other Laibin People's Hospital trials
Trials by the same sponsor.
- NCT05934461 — A Retrospective Study of Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant Lung Cancer · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05994339 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Laibin People's Hospital
- Last refreshed: 29 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05994339.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing